Parp Inhibitor Biomarkers Market Size to Exceed USD 6,709.1 Mn by 2032

The Parp Inhibitor Biomarkers Market, estimated at USD 1,414.9 Mn in 2025, is expected to exhibit a CAGR of 24.9% and reach USD 6,709.1 Mn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

Key market players are focused on adopting growth strategies such as partnerships, which will drive the global PARP Inhibitor Biomarkers market. For instance, in May 2025, Horizon Therapeutics Public Ltd. Co., a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases in Dublin, in partnership with Invitae Corporation is a biotechnology company that was created as a subsidiary of Genomic Health, announced a urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people, including their family members. Horizon’s support of the PARP Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.

Global PARP Inhibitor Biomarkers Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of thingss from one place to another.

COVID-19 had a positive impact on the global PARP Inhibitor Biomarkers market..For instance, in April 2025, Siemens Healthcare GmbH, a medical device company. It is the parent company for several medical technology companies and is headquartered in Erlangen, Germany, formally unveiled the RAPIDPoint 500e Cancer Blood Biomarker, adding to the company's product lineup and supporting COVID-19 initiatives. This is assisting in raising the revenue for the line.

Global PARP Inhibitor Biomarkers Market: Key Developments

In July 2025, Beckman Coulter, a clinical diagnostics company, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Under the terms of the agreements, Quidel will continue to manufacture and supply certain components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively manufacture and sell to customers the BNP assay currently sold as TRIAGE BNP by Quidel, under the brand name Access BNP.

In May 2025, F. Hoffmann-La Roche Ltd. is a multinational healthcare company based in Switzerland, announced its acquisition of Stratos Genomics. The development of diagnostic sequencing based on DNA was made possible by this acquisition. This enhanced the business's healthcare diagnosing division and raised its revenue-generating capacity.

In September 2025, Labcorp is a life sciences company based in the U.S., announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra Cancer (RA) assay.

In June 2025, the University of Montreal Hospital Research Centre (CRCHUM) developed a two-step combination therapy for the treatment of ovarian cancer. According to the research, the combination of chemotherapy and PARP inhibitors can assist in reducing the proliferation of cancer cells and destroy them.

Browse 34 Market Data Tables and 26 Figures spread through 176 Pages and in-depth TOC on “Global PARP Inhibitor Biomarkers Market”- Forecast to 2032, Global PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.)  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/parp-inhibitor-biomarkers-market-3762

Key Takeaways of the Global PARP Inhibitor Biomarkers Market :

• The global PARP Inhibitor Biomarkers market is expected to exhibit a CAGR of 24.9% during the forecast period.The merger with emerging economies offers lucrative growth opportunities for players in the global PARP Inhibitor Biomarkers market.
• Among Services, the BRCA 1 & 2 Testing segment is expected to hold a dominant position in the global PARP Inhibitor Biomarkers market during the forecast period and this is attributed to the increasing novel treatment of PARP biomarkers in the field of PARP Inhibitor Biomarkers. In April 2025, according to study published in The New England Journal of Medicine, results showed men with metastatic castration-resistant prostate cancer (mCRPC) on a novel hormone treatment experienced significant, clinical improvement from Olaparib (a PARP inhibitor) in radiographic-progression-free survival compared to men on novel hormone treatment alone. The patient populations shared mutations in BRCA1, BRCA2, ATM and/or other HRR genes. The subjects receiving Olaparib also trended toward an average improved overall survival of 18 months compared to an average of 14.7 months in the other cohorts.
• Among region, North America is expected to be the dominant region in the global PARP Inhibitor Biomarkers market, owing to the key players are focusing on organic strategies start new test launch. For instance, in November 2025, Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies in North America, announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to PrismRA. PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with Cancer.
• Major players operating in the Global PARP Inhibitor Biomarkers Market Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc.,Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB and Thermo Fisher Scientifi Inc.